RE: pharma-trade-war9 Feb 2022 20:35
In a word Yes. Taken from interview the other day
Q2: Can you tell us more about your exclusive early lung cancer diagnostic technology and what it does?
A2: "The answer is, it’s been in the making for a number of years now, it was actually created at the University of York by Professor Dawn Coverley who identified a protein that is circulating in people’s blood called CIZ1b, hence the name of our company.
This CIZ1b protein is a very important biomarker because the identification of it in your blood indicates that you have a very early stage lung cancer. That is important because the earlier that you can detect the presence of a lung cancer, the greater is the chance that you can intervene surgically or with some other therapeutic and actually cure the person. The problem with this disease is that if it is not detected until it’s much later, then unfortunately the survival rates drop off quite dramatically.
It’s so important to have an early stage lung cancer test and, I’m not sure if your listeners know, tomorrow is World Cancer Day and so it’s very important that signing this deal this week and we’ll have something to say about that tomorrow as well, is that one of the best ways of defeating cancer is to detect it early.
So, we are working very hard to develop this test so that it becomes available not just here in the UK, but in China and elsewhere in the world."